Stephanos joined H3 in 2019 and serves as Vice President, Head of Chemistry, bringing over 17 years of experience in oncology and neuroscience drug development to the H3 team. Prior to joining H3, Stephanos led the protein homeostasis and early discovery areas at FORMA Therapeutics, which included overseeing the discovery of novel small molecules of deubiquitinase (DUB) enzymes and initiating the neurodegenerative diseases (NDD) therapeutic area. Before FORMA, he spent eleven years at AstraZeneca’s R&D department leading multiple drug discovery teams from concept to clinic. Stephanos has extensive experience managing collaborative projects with internal and external stakeholders in both industry and academia to produce multiple INDs.
Stephanos received his Ph.D. in organic chemistry from the Imperial College London and subsequently was a post-doctoral fellow under the leadership of Professor Yoshito Kishi at Harvard University. He earned his B.S. in chemistry and biochemistry from King’s College London.